SVB Leerink Maintains Outperform on Humana, Raises Price Target to $535
SVB Leerink analyst Whit Mayo maintains Humana (NYSE:HUM) with a Outperform and raises the price target from $525 to $535.
Earnings Scheduled For April 27, 2022
Companies Reporting Before The Bell
• Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.
Watching Shares Of Humana; CNBC Mentions Stock In Article ‘CNBC Investing Club Says: We’re bulking up on this health insurance stock that we added recently from our watch list’
https://www.cnbc.com/2022/04/21/investing-club-were-bulking-up-on-this-health-insurance-stock-that-we-added-recently-from-our-watch-list.html?utm_term=Autofeed&utm_medium=Social&utm_content=Main&utm_source=Tw
Humana to Offload Substantial Stake In Kindred At Home Hospice & Personal Care Divisions
Humana Inc (NYSE:HUM) has agreed to divest a majority interest in the Hospice and Personal Care divisions of Humana’s Kindred at…
Humana in Advanced Talks to Sell Hospice Business Kindred at Home to CD&R in Deal Valued at ~$3B
-Bloomberg
Humana in Advanced Talks to Sell Hospice Business to CD&R
If You Invested $100 In Humana 10 Years Ago, Here’s How Much You Would Have Today
Humana (NYSE:HUM) has outperformed the market over the past 10 years by 5.55% on an annualized basis producing an average annual return of 18.03%. Currently, Humana has a market capitalization of $59.08 billion.
Looking Into Humana Inc’s Recent Short Interest
Humana Inc's (NYSE:HUM) short percent of float has fallen 16.42% since its last report. The company recently reported that it has 1.44 million shares sold short, which is 1.12% of all regular shares that are available for trading.
Humana Shares Move To Recent High Following CNBC Article Highlighting Stock As An Investing Club Pick: ‘We’re adding a Bullpen stock to the portfolio, one day after putting it on our watch list’
https://www.cnbc.com/2022/04/19/investing-club-were-adding-a-bullpen-stock-to-the-portfolio-one-day-after-putting-it-on-our-watch-list.html
UBS Upgrades Rating to Buy for Humana, Raises Price Target To $520
UBS upgraded its rating of Humana (NYSE:HUM) to Buy with a price target of $520.00, changing its price target from $486.00 to $520.00.
Shares of Humana are trading up 2.2% over the last 24 hours, at $458.92 per share.
A move to $520.00 would account for a 13.31% increase from the current share price.
UBS Upgrades Humana to Buy, Raises Price Target to $520
UBS analyst Kevin Caliendo upgrades Humana (NYSE:HUM) from Neutral to Buy and raises the price target from $486 to $520.